Adams Clare M, Hiebert Scott W, Eischen Christine M
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Biochemistry, Vanderbilt University Medical Center, Nashville, Tennessee.
Cancer Res. 2016 Feb 1;76(3):736-48. doi: 10.1158/0008-5472.CAN-15-1751. Epub 2015 Dec 16.
Alterations in the expression or function of histone deacetylases (HDAC) contribute to the development and progression of hematologic malignancies. Consequently, the development and implementation of HDAC inhibitors has proven to be therapeutically beneficial, particularly for hematologic malignancies. However, the molecular mechanisms by which HDAC inhibition (HDACi) induces tumor cell death remain unresolved. Here, we investigated the effects of HDACi in Myc-driven B-cell lymphoma and five other hematopoietic malignancies. We determined that Myc-mediated transcriptional repression of the miR-15 and let-7 families in malignant cells was relieved upon HDACi, and Myc was required for their upregulation. The miR-15 and let-7 families then targeted and downregulated the antiapoptotic genes Bcl-2 and Bcl-xL, respectively, to induce HDACi-mediated apoptosis. Notably, Myc also transcriptionally upregulated these miRNA in untransformed cells, indicating that this Myc-induced miRNA-mediated apoptotic pathway is suppressed in malignant cells, but becomes reactivated upon HDACi. Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells.
组蛋白去乙酰化酶(HDAC)表达或功能的改变有助于血液系统恶性肿瘤的发生和发展。因此,HDAC抑制剂的开发和应用已被证明具有治疗益处,特别是对血液系统恶性肿瘤。然而,HDAC抑制(HDACi)诱导肿瘤细胞死亡的分子机制仍未明确。在此,我们研究了HDACi对Myc驱动的B细胞淋巴瘤和其他五种血液系统恶性肿瘤的影响。我们确定,HDACi作用后,恶性细胞中Myc介导的miR-15和let-7家族的转录抑制被解除,且Myc是它们上调所必需的。然后,miR-15和let-7家族分别靶向并下调抗凋亡基因Bcl-2和Bcl-xL,以诱导HDACi介导的凋亡。值得注意的是,Myc在未转化细胞中也转录上调这些miRNA,这表明这种Myc诱导的miRNA介导的凋亡途径在恶性细胞中受到抑制,但在HDACi作用后会重新激活。综上所述,我们的结果揭示了一种此前未知的机制,即Myc在恶性造血细胞中独立于p53途径并作为对HDACi的反应诱导凋亡。